1
|
Dong N, Ali-Khiavi P, Ghavamikia N, Pakmehr S, Sotoudegan F, Hjazi A, Gargari MK, Gargari HK, Behnamrad P, Rajabi M, Elhami A, Saffarfar H, Nourizadeh M. Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology. Neurol Sci 2025; 46:1489-1507. [PMID: 39638950 DOI: 10.1007/s10072-024-07871-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Accepted: 10/29/2024] [Indexed: 12/07/2024]
Abstract
Alzheimer's disease (AD) remains a formidable challenge in the field of neurodegenerative disorders, necessitating innovative therapeutic strategies. Nanomedicine, leveraging nanomaterials, has emerged as a promising avenue for AD treatment, with a key emphasis on overcoming the blood-brain barrier (BBB) to enhance drug delivery efficiency. This review provides a comprehensive analysis of recent advancements in the application of nanomaterials for AD therapy, highlighting their unique properties and functions. The blood-brain barrier, a complex physiological barrier, poses a significant hurdle for traditional drug delivery to the brain. Nanomedicine addresses this challenge by utilizing various nanomaterials such as liposomes, polymeric nanoparticles, and metal nanoparticles. These nanocarriers enable improved drug bioavailability, sustained release, and targeted delivery to specific brain regions affected by AD pathology. The review discusses the diverse range of nanomaterials employed in AD treatment, exploring their capacity to encapsulate therapeutic agents, modulate drug release kinetics, and enhance drug stability. Additionally, the multifunctionality of nanomaterials allows for simultaneous imaging and therapy, facilitating early diagnosis and intervention. Key aspects covered include the interaction of nanomaterials with Aβ aggregates, the role of antioxidants in mitigating oxidative stress, and the potential of nanomedicine in alleviating neuroinflammation associated with AD. Furthermore, the safety, biocompatibility, and toxicity profiles of various nanomaterials are scrutinized to ensure their clinical applicability. In conclusion, this review underscores the pivotal role of nanomedicine and nanomaterials in revolutionizing AD treatment strategies. By specifically addressing BBB challenges, these innovative approaches offer new avenues for targeted drug delivery and improved therapeutic outcomes in the complex landscape of Alzheimer's disease.
Collapse
Affiliation(s)
- Nana Dong
- College of Basic Medical Sciences, China Three Gorges University, 443000, Yichang, Hubei Province, China
| | - Payam Ali-Khiavi
- Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
| | - Nima Ghavamikia
- Cardiovascular Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Farzaneh Sotoudegan
- Quality Control of Medicines and Supplements Group, Pharmaceutical Quality Assurance Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
| | - Ahmed Hjazi
- Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia
| | | | | | - Parisa Behnamrad
- Department of Pharmaceutics, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
| | | | - Anis Elhami
- Faculty of Dentistry, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Hossein Saffarfar
- Cardiovascular Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Mehrdad Nourizadeh
- Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
2
|
Allakhverdiev ES, Kossalbayev BD, Sadvakasova AK, Bauenova MO, Belkozhayev AM, Rodnenkov OV, Martynyuk TV, Maksimov GV, Allakhverdiev SI. Spectral insights: Navigating the frontiers of biomedical and microbiological exploration with Raman spectroscopy. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY. B, BIOLOGY 2024; 252:112870. [PMID: 38368635 DOI: 10.1016/j.jphotobiol.2024.112870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 01/04/2024] [Accepted: 02/14/2024] [Indexed: 02/20/2024]
Abstract
Raman spectroscopy (RS), a powerful analytical technique, has gained increasing recognition and utility in the fields of biomedical and biological research. Raman spectroscopic analyses find extensive application in the field of medicine and are employed for intricate research endeavors and diagnostic purposes. Consequently, it enjoys broad utilization within the realm of biological research, facilitating the identification of cellular classifications, metabolite profiling within the cellular milieu, and the assessment of pigment constituents within microalgae. This article also explores the multifaceted role of RS in these domains, highlighting its distinct advantages, acknowledging its limitations, and proposing strategies for enhancement.
Collapse
Affiliation(s)
- Elvin S Allakhverdiev
- National Medical Research Center of Cardiology named after academician E.I. Chazov, Academician Chazov 15А St., Moscow 121552, Russia; Department of Biophysics, Faculty of Biology, Lomonosov Moscow State University, Moscow, Leninskie Gory 1/12, Moscow 119991, Russia.
| | - Bekzhan D Kossalbayev
- Ecology Research Institute, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkistan, Kazakhstan; Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, No. 32, West 7th Road, Tianjin Airport Economic Area, 300308 Tianjin, China; Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty 050038, Kazakhstan; Department of Chemical and Biochemical Engineering, Institute of Geology and Oil-Gas Business Institute Named after K. Turyssov, Satbayev University, Almaty 050043, Kazakhstan
| | - Asemgul K Sadvakasova
- Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty 050038, Kazakhstan
| | - Meruyert O Bauenova
- Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty 050038, Kazakhstan
| | - Ayaz M Belkozhayev
- Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty 050038, Kazakhstan; Department of Chemical and Biochemical Engineering, Institute of Geology and Oil-Gas Business Institute Named after K. Turyssov, Satbayev University, Almaty 050043, Kazakhstan; M.A. Aitkhozhin Institute of Molecular Biology and Biochemistry, Almaty 050012, Kazakhstan
| | - Oleg V Rodnenkov
- National Medical Research Center of Cardiology named after academician E.I. Chazov, Academician Chazov 15А St., Moscow 121552, Russia
| | - Tamila V Martynyuk
- National Medical Research Center of Cardiology named after academician E.I. Chazov, Academician Chazov 15А St., Moscow 121552, Russia
| | - Georgy V Maksimov
- Department of Biophysics, Faculty of Biology, Lomonosov Moscow State University, Moscow, Leninskie Gory 1/12, Moscow 119991, Russia
| | - Suleyman I Allakhverdiev
- K.A. Timiryazev Institute of Plant Physiology, Russian Academy of Sciences, Botanicheskaya Street 35, Moscow 127276, Russia; Institute of Basic Biological Problems, FRC PSCBR Russian Academy of Sciences, Pushchino 142290, Russia; Faculty of Engineering and Natural Sciences, Bahcesehir University, Istanbul, Turkey.
| |
Collapse
|
3
|
Saresella M, Zoia CP, La Rosa F, Bazzini C, Sala G, Grassenis E, Marventano I, Hernis A, Piancone F, Conti E, Sesana S, Re F, Seneci P, Ferrarese C, Clerici M. Glibenclamide-Loaded Engineered Nanovectors (GNVs) Modulate Autophagy and NLRP3-Inflammasome Activation. Pharmaceuticals (Basel) 2023; 16:1725. [PMID: 38139851 PMCID: PMC10747596 DOI: 10.3390/ph16121725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 12/01/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023] Open
Abstract
Activation of the NLRP3 inflammasome in response to either exogenous (PAMPs) or endogenous (DAMPs) stimuli results in the production of IL-18, caspase-1 and IL-1β. These cytokines have a beneficial role in promoting inflammation, but an excessive activation of the inflammasome and the consequent constitutive inflammatory status plays a role in human pathologies, including Alzheimer's disease (AD). Autophagic removal of NLRP3 inflammasome activators can reduce inflammasome activation and inflammation. Likewise, inflammasome signaling pathways regulate autophagy, allowing the development of inflammatory responses but preventing excessive and detrimental inflammation. Nanotechnology led to the development of liposome engineered nanovectors (NVs) that can load and carry drugs. We verified in an in vitro model of AD-associated inflammation the ability of Glibenclamide-loaded NVs (GNVs) to modulate the balance between inflammasome activation and autophagy. Human THP1dM cells were LPS-primed and oligomeric Aß-stimulated in the presence/absence of GNVs. IL-1β, IL-18 and activated caspase-1 production was evaluated by the Automated Immunoassay System (ELLA); ASC speck formation (a marker of NLRP3 activation) was analyzed by FlowSight Imaging flow-cytometer (AMNIS); the expression of autophagy targets was investigated by RT-PCR and Western blot (WB); and the modulation of autophagy-related up-stream signaling pathways and Tau phosphorylation were WB-quantified. Results showed that GNVs reduce activation of the NLRP3 inflammasome and prevent the Aß-induced phosphorylation of ERK, AKT, and p70S6 kinases, potentiating autophagic flux and counteracting Tau phosphorylation. These preliminary results support the investigation of GNVs as a possible novel strategy in disease and rehabilitation to reduce inflammasome-associated inflammation.
Collapse
Affiliation(s)
- Marina Saresella
- IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy; (M.S.); (I.M.); (A.H.); (F.P.); (M.C.)
| | - Chiara Paola Zoia
- Neurobiology Laboratory, School of Medicine and Surgery, University of Study of Milano-Bicocca, 20900 Monza, Italy; (C.P.Z.); (C.B.); (G.S.); (E.G.); (E.C.); (C.F.)
- Milan Center for Neuroscience, University of Study of Milano-Bicocca, 20126 Milano, Italy
| | - Francesca La Rosa
- IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy; (M.S.); (I.M.); (A.H.); (F.P.); (M.C.)
| | - Chiara Bazzini
- Neurobiology Laboratory, School of Medicine and Surgery, University of Study of Milano-Bicocca, 20900 Monza, Italy; (C.P.Z.); (C.B.); (G.S.); (E.G.); (E.C.); (C.F.)
- Milan Center for Neuroscience, University of Study of Milano-Bicocca, 20126 Milano, Italy
| | - Gessica Sala
- Neurobiology Laboratory, School of Medicine and Surgery, University of Study of Milano-Bicocca, 20900 Monza, Italy; (C.P.Z.); (C.B.); (G.S.); (E.G.); (E.C.); (C.F.)
- Milan Center for Neuroscience, University of Study of Milano-Bicocca, 20126 Milano, Italy
| | - Erica Grassenis
- Neurobiology Laboratory, School of Medicine and Surgery, University of Study of Milano-Bicocca, 20900 Monza, Italy; (C.P.Z.); (C.B.); (G.S.); (E.G.); (E.C.); (C.F.)
- Milan Center for Neuroscience, University of Study of Milano-Bicocca, 20126 Milano, Italy
| | - Ivana Marventano
- IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy; (M.S.); (I.M.); (A.H.); (F.P.); (M.C.)
| | - Ambra Hernis
- IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy; (M.S.); (I.M.); (A.H.); (F.P.); (M.C.)
| | - Federica Piancone
- IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy; (M.S.); (I.M.); (A.H.); (F.P.); (M.C.)
| | - Elisa Conti
- Neurobiology Laboratory, School of Medicine and Surgery, University of Study of Milano-Bicocca, 20900 Monza, Italy; (C.P.Z.); (C.B.); (G.S.); (E.G.); (E.C.); (C.F.)
- Milan Center for Neuroscience, University of Study of Milano-Bicocca, 20126 Milano, Italy
| | - Silvia Sesana
- BioNanoMedicine Center NANOMIB, School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy; (S.S.); (F.R.)
| | - Francesca Re
- BioNanoMedicine Center NANOMIB, School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy; (S.S.); (F.R.)
| | - Pierfausto Seneci
- Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milan, Italy;
| | - Carlo Ferrarese
- Neurobiology Laboratory, School of Medicine and Surgery, University of Study of Milano-Bicocca, 20900 Monza, Italy; (C.P.Z.); (C.B.); (G.S.); (E.G.); (E.C.); (C.F.)
- Milan Center for Neuroscience, University of Study of Milano-Bicocca, 20126 Milano, Italy
- Department of Neuroscience, IRCC Fondazione S. Gerardo dei Tintori, 20900 Monza, Italy
| | - Mario Clerici
- IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy; (M.S.); (I.M.); (A.H.); (F.P.); (M.C.)
- Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy
| |
Collapse
|
4
|
Lukhele BS, Bassey K, Witika BA. The Utilization of Plant-Material-Loaded Vesicular Drug Delivery Systems in the Management of Pulmonary Diseases. Curr Issues Mol Biol 2023; 45:9985-10017. [PMID: 38132470 PMCID: PMC10742082 DOI: 10.3390/cimb45120624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 12/01/2023] [Accepted: 12/04/2023] [Indexed: 12/23/2023] Open
Abstract
Medicinal plants have been utilized to treat a variety of conditions on account of the bioactive properties that they contain. Most bioactive constituents from plants are of limited effectiveness, due to poor solubility, limited permeability, first-pass metabolism, efflux transporters, chemical instability, and food-drug interactions However, when combined with vesicular drug delivery systems (VDDS), herbal medicines can be delivered at a predetermined rate and can exhibit site-specific action. Vesicular drug delivery systems are novel pharmaceutical formulations that make use of vesicles as a means of encapsulating and transporting drugs to various locations within the body; they are a cutting-edge method of medication delivery that combats the drawbacks of conventional drug delivery methods. Drug delivery systems offer promising strategies to overcome the bioavailability limitations of bioactive phytochemicals. By improving their solubility, protecting them from degradation, enabling targeted delivery, and facilitating controlled release, drug delivery systems can enhance the therapeutic efficacy of phytochemicals and unlock their full potential in various health conditions. This review explores and collates the application of plant-based VDDS with the potential to exhibit protective effects against lung function loss in the interest of innovative and effective treatment and management of respiratory illnesses.
Collapse
Affiliation(s)
| | - Kokoette Bassey
- Department of Pharmaceutical Sciences, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 0204, South Africa;
| | - Bwalya Angel Witika
- Department of Pharmaceutical Sciences, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 0204, South Africa;
| |
Collapse
|
5
|
Picciolini S, Rodà F, Gualerzi A, Mangolini V, Forleo L, Mangolini A, Sesana S, Antoniou A, Re F, Seneci P, Bedoni M. SPRi analysis of molecular interactions of mApoE-functionalized liposomes as drug delivery systems for brain diseases. Analyst 2023; 148:6070-6077. [PMID: 37904570 DOI: 10.1039/d3an01507f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2023]
Abstract
The application of liposomes (LPs) to central nervous system disorders could represents a turning point in the therapy and quality of life of patients. Indeed, LPs have demonstrated their ability to cross the blood-brain barrier (BBB) and, as a consequence, to enhance the therapeutics delivery into the brain. Some approaches for BBB crossing involve the modification of LP surfaces with biologically active ligands. Among them, the Apolipoprotein E-modified peptide (mApoE) has been used for several LP-based nanovectors under investigation. In this study, we propose Surface Plasmon Resonance imaging (SPRi) for the characterization of multifunctionalized LPs for Glioblastoma treatment. LPs were functionalized with mApoE and with a metallo-protease sensitive lipopeptide to deliver and guarantee the localized release of an encapsulated drug in diseased areas. The SPRi analysis was optimized in order to evaluate the binding affinity between LPs and mApoE receptors, finding that mApoE-LPs generated SPRi signals referred to interactions between mApoE and receptors mainly present in the brain. Moreover, a significant binding between LPs and VCAM-1 (endothelial receptor) was observed, whereas LPs did not interact significantly with peripheral receptors expressed on monocytes and lymphocytes. SPRi results confirmed not only the presence of mApoE on LP surfaces, but also its binding affinity, thanks to the specific interaction with selected receptors. In conclusion, the high sensitivity and the multiplexing capability associated with the low volumes of sample required and the minimal sample preparation, make SPRi an excellent technique for the characterization of multifunctionalized nanoparticles-based formulations.
Collapse
Affiliation(s)
| | - Francesca Rodà
- IRCCS Fondazione Don Carlo Gnocchi Onlus, Milano, Italy.
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Alice Gualerzi
- IRCCS Fondazione Don Carlo Gnocchi Onlus, Milano, Italy.
| | - Valentina Mangolini
- IRCCS Fondazione Don Carlo Gnocchi Onlus, Milano, Italy.
- Dipartimento di Medicina Molecolare e Traslazionale, Università degli Studi di Brescia, Brescia, Italy
| | - Luana Forleo
- IRCCS Fondazione Don Carlo Gnocchi Onlus, Milano, Italy.
| | | | - Silvia Sesana
- School of Medicine and Surgery, University of Milano-Bicocca, Vedano al Lambro, Italy
| | - Antonia Antoniou
- Chemistry Department, Università Statale di, Milano, Milano, Italy
| | - Francesca Re
- School of Medicine and Surgery, University of Milano-Bicocca, Vedano al Lambro, Italy
| | | | - Marzia Bedoni
- IRCCS Fondazione Don Carlo Gnocchi Onlus, Milano, Italy.
| |
Collapse
|